{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:37:08Z","timestamp":1791023828897,"version":"4.1.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1038\/ncponc0663","type":"journal-article","created":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T10:37:51Z","timestamp":1164969471000},"page":"682-692","source":"Crossref","is-referenced-by-count":95,"title":["Drug Insight: vascular disrupting agents and angiogenesis\u2014novel approaches for drug delivery"],"prefix":"10.1038","volume":"3","author":[{"given":"Matthew M","family":"Cooney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem","family":"van Heeckeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam","family":"Bhakta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scot C","family":"Remick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFncponc0663_CR1","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/BF01653556","volume":"6","author":"J Okamura","year":"1982","unstructured":"Okamura J  et al. (1982) An appraisal of transcatheter arterial embolization combined with transcatheter arterial infusion of chemotherapeutic agent for hepatic malignancies. World J Surg 6: 352\u2013357","journal-title":"World J Surg"},{"key":"BFncponc0663_CR2","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1002\/1097-0142(19830415)51:8<1359::AID-CNCR2820510807>3.0.CO;2-V","volume":"51","author":"YZ Patt","year":"1983","unstructured":"Patt YZ  et al. (1983) Hepatic arterial chemotherapy and occlusion for palliation of primary hepatocellular and unknown primary neoplasms in the liver. Cancer 51: 1359\u20131363","journal-title":"Cancer"},{"key":"BFncponc0663_CR3","first-page":"77","volume":"8","author":"MC Soulen","year":"1994","unstructured":"Soulen MC (1994) Chemoembolization of hepatic malignancies. Oncology 8: 77\u201384","journal-title":"Oncology"},{"issue":"Suppl","key":"BFncponc0663_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/0167-8140(91)90196-N","volume":"20","author":"J Denekamp","year":"1991","unstructured":"Denekamp J  et al. (1991) Angiogenic attack as a therapeutic strategy for cancer. Radiother Oncol 20 (Suppl): 103\u2013112","journal-title":"Radiother Oncol"},{"key":"BFncponc0663_CR5","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1126\/science.279.5349.377","volume":"279","author":"W Arap","year":"1999","unstructured":"Arap W  et al. (1999) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279: 377\u2013380","journal-title":"Science"},{"key":"BFncponc0663_CR6","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJM199808133390711","volume":"339","author":"JE Schnitzer","year":"1998","unstructured":"Schnitzer JE (1998) Vascular targeting as a strategy for cancer therapy. N Engl J Med 339: 472\u2013474","journal-title":"N Engl J Med"},{"key":"BFncponc0663_CR7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S1470-2045(00)00224-2","volume":"2","author":"J Griggs","year":"2001","unstructured":"Griggs J  et al. (2001) Targeting tumour vasculature: the development of combretastatin A4. Lancet Oncol 2: 82\u201387","journal-title":"Lancet Oncol"},{"key":"BFncponc0663_CR8","first-page":"203","volume":"24","author":"JM Pluda","year":"1997","unstructured":"Pluda JM (1997) Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Semin Oncol 24: 203\u2013218","journal-title":"Semin Oncol"},{"key":"BFncponc0663_CR9","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nm0603-685","volume":"9","author":"RK Jain","year":"2003","unstructured":"Jain RK (2003) Molecular regulation of vessel maturation. Nat Med 9: 685\u2013693","journal-title":"Nat Med"},{"key":"BFncponc0663_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","volume":"307","author":"RK Jain","year":"2005","unstructured":"Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58\u201362","journal-title":"Science"},{"key":"BFncponc0663_CR11","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nrc1627","volume":"5","author":"D Neri","year":"2005","unstructured":"Neri D  et al. (2005) Tumor vascular targeting. Nat Rev Cancer 5: 436\u2013446","journal-title":"Nat Rev Cancer"},{"key":"BFncponc0663_CR12","first-page":"6387","volume":"6","author":"Y Matsumura","year":"1986","unstructured":"Matsumura Y  et al. (1986) A new concept for macro-molecular therapeutics in cancer chemotherapy: mechanisms of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res 6: 6387\u20136392","journal-title":"Cancer Res"},{"key":"BFncponc0663_CR13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1172\/JCI5028","volume":"103","author":"LE Benjamin","year":"1999","unstructured":"Benjamin LE  et al. (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103: 159\u2013165","journal-title":"J Clin Invest"},{"key":"BFncponc0663_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1172\/JCI6127","volume":"103","author":"DC Darland","year":"1999","unstructured":"Darland DC  et al. (1999) Blood vessel maturation: vascular development comes of age. J Clin Invest 103: 157\u2013158","journal-title":"J Clin Invest"},{"key":"BFncponc0663_CR15","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1038\/bjc.1996.320","volume":"74","author":"DJ Chaplin","year":"1996","unstructured":"Chaplin DJ  et al. (1996) Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br J Cancer 74: S86\u2013S88","journal-title":"Br J Cancer"},{"key":"BFncponc0663_CR16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/ijc.2910630121","volume":"63","author":"SA Hill","year":"1995","unstructured":"Hill SA  et al. (1995) Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. Int J Cancer 63: 199\u2013223","journal-title":"Int J Cancer"},{"key":"BFncponc0663_CR17","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/0277-5379(89)90072-2","volume":"25","author":"DJ Kerr","year":"1989","unstructured":"Kerr DJ  et al. (1989) Flavone acetic acid\u2014preclinical and clinical activity. Eur J Cancer Clin Oncol 25: 1271\u20131272","journal-title":"Eur J Cancer Clin Oncol"},{"key":"BFncponc0663_CR18","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0959-8049(05)80355-7","volume":"29","author":"GG Chabot","year":"1993","unstructured":"Chabot GG  et al. (1993) Tumour necrosis factor-alpha plasma levels after flavone acetic acid administration in man and mouse. Eur J Cancer 29: 729\u2013733","journal-title":"Eur J Cancer"},{"key":"BFncponc0663_CR19","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/0277-5379(89)90099-0","volume":"25","author":"SA Hill","year":"1989","unstructured":"Hill SA  et al. (1989) Vascular collapse after flavone acetic acid: a possible mechanism of its antitumour action. Eur J Cancer 25: 1419\u20131424","journal-title":"Eur J Cancer"},{"key":"BFncponc0663_CR20","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/0277-5379(91)90391-P","volume":"27","author":"BC Baguley","year":"1991","unstructured":"Baguley BC  et al. (1991) Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicines: evidence for a vascular mechanism. Eur J Cancer 27: 482\u2013487","journal-title":"Eur J Cancer"},{"key":"BFncponc0663_CR21","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/0959-8049(93)90082-Q","volume":"29","author":"SA Hill","year":"1993","unstructured":"Hill SA  et al. (1993) Vinca alkaloids: anti-vascular effects in a murine tumour. Eur J Cancer 29: 1320\u20131324","journal-title":"Eur J Cancer"},{"key":"BFncponc0663_CR22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/jnci\/81.3.216","volume":"81","author":"MC Bibby","year":"1989","unstructured":"Bibby MC  et al. (1989) Reduction of tumor blood flow by flavone acetic acid: a possible component to therapy. J Natl Cancer Inst 81: 216\u2013220","journal-title":"J Natl Cancer Inst"},{"key":"BFncponc0663_CR23","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/bjc.1989.312","volume":"60","author":"F Kallinowski","year":"1989","unstructured":"Kallinowski F  et al. (1989) In vivo targets of recombinant human tumour necrosis factor-alpha blood flow, oxygen consumption and growth of isotransplanted rat tumours. Br J Cancer 60: 555\u2013560","journal-title":"Br J Cancer"},{"key":"BFncponc0663_CR24","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/jnci\/81.13.1005","volume":"81","author":"LJ Zwi","year":"1989","unstructured":"Zwi LJ  et al. (1989) Blood flow failure as a major determinant in the anti-tumor action of flavone acetic acid. J Natl Cancer Inst 81: 1005\u20131013","journal-title":"J Natl Cancer Inst"},{"key":"BFncponc0663_CR25","first-page":"89","volume":"6","author":"RJ Ludford","year":"1985","unstructured":"Ludford RJ (1985) Colchicine in the experimental chemotherapy of cancer. J Natl Cancer Inst 6: 89\u2013101","journal-title":"J Natl Cancer Inst"},{"key":"BFncponc0663_CR26","first-page":"1829","volume":"57","author":"GG Dark","year":"1997","unstructured":"Dark GG  et al. (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57: 1829\u20131834","journal-title":"Cancer Res"},{"key":"BFncponc0663_CR27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1158\/1078-0432.CCR-0364-3","volume":"10","author":"MM Cooney","year":"2004","unstructured":"Cooney MM  et al. (2004) Cardiovascular safety profile of combretastatin A4 phosphate (CA4P) in a single-dose phase I pharmacokinetic study in patients with advanced cancer. Clin Cancer Res 10: 96\u2013100","journal-title":"Clin Cancer Res"},{"key":"BFncponc0663_CR28","doi-asserted-by":"publisher","first-page":"5967","DOI":"10.1158\/1078-0432.CCR-04-0534","volume":"10","author":"M Varterasian","year":"2004","unstructured":"Varterasian M  et al. (2004) Letter to Editor. Consideration of QT\/QTc interval data in a phase I study in patients with advanced cancer. Clin Cancer Res 10: 5967\u20135969","journal-title":"Clin Cancer Res"},{"key":"BFncponc0663_CR29","doi-asserted-by":"publisher","first-page":"5967","DOI":"10.1158\/1078-0432.CCR-0364-3","volume":"10","author":"MM Cooney","year":"2004","unstructured":"Cooney MM  et al. (2004) Invited Letter to the Editor in response to Varterasian M  et al. letter\/commentary on the cardiovascular safety profile of combretastatin A4 phosphate in a single-dose phase I trial in patients with advanced cancer. Clin Cancer Res 10: 5967\u20135969","journal-title":"Clin Cancer Res"},{"key":"BFncponc0663_CR30","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.2005.04.8801","volume":"24","author":"WJ van Heeckeren","year":"2006","unstructured":"van Heeckeren WJ  et al. (2006) The promise of new vascular disrupting agents balanced with cardiac toxicity: is it time that oncologists get to know their cardiologists? J Clin Oncol 24: 1485\u20131488","journal-title":"J Clin Oncol"},{"key":"BFncponc0663_CR31","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197108122850711","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182\u20131186","journal-title":"N Engl J Med"},{"key":"BFncponc0663_CR32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/jnci\/82.1.4","volume":"82","author":"J Folkman","year":"1990","unstructured":"Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4\u20136","journal-title":"J Natl Cancer Inst"},{"key":"BFncponc0663_CR33","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/carcin\/21.3.505","volume":"21","author":"RS Kerbel","year":"2000","unstructured":"Kerbel RS (2000) Tumor angiogenesis: past, present, and near future. Carcinogenesis 21: 505\u2013515","journal-title":"Carcinogenesis"},{"key":"BFncponc0663_CR34","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal S  et al. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341: 1565\u20131571","journal-title":"N Engl J"},{"key":"BFncponc0663_CR35","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H  et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335\u20132342","journal-title":"N Engl J Med"},{"key":"BFncponc0663_CR36","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nrc1369","volume":"6","author":"RS Kerbel","year":"2004","unstructured":"Kerbel RS  et al. (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 6: 423\u2013436","journal-title":"Nat Rev Cancer"},{"key":"BFncponc0663_CR37","first-page":"3878s","volume":"5","author":"BA Teicher","year":"1999","unstructured":"Teicher BA (1999) Combination of antiangiogenic agents with standard cytotoxic therapies in therapeutic regimens. Clin Cancer Res 5: 3878s\u20133879s.","journal-title":"Clin Cancer Res"},{"key":"BFncponc0663_CR38","first-page":"6702","volume":"52","author":"BA Teicher","year":"1992","unstructured":"Teicher BA  et al. (1992) Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52: 6702\u20136704","journal-title":"Cancer Res"},{"key":"BFncponc0663_CR39","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa021491","volume":"349","author":"JC Yang","year":"2003","unstructured":"Yang JC  et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427\u2013434","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"BFncponc0663_CR40","first-page":"2S","volume":"23","author":"AB Sandler","year":"2005","unstructured":"Sandler AB  et al (2005) Randomized phase II\/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) trial\u2014E4599 [abstract]. Proc Am Soc Clin Oncol 23 (Suppl): 2S","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BFncponc0663_CR41","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nm988","volume":"10","author":"CG Willett","year":"2004","unstructured":"Willett CG  et al. (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10: 145\u2013147","journal-title":"Nat Med"},{"key":"BFncponc0663_CR42","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1053\/srao.2003.50005","volume":"13","author":"DW Siemann","year":"2003","unstructured":"Siemann DW and Shi W (2003) Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy. Semin Radiat Oncol 13: 53\u201361","journal-title":"Semin Radiat Oncol"},{"key":"BFncponc0663_CR43","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/S0093-7754(01)90287-8","volume":"28","author":"LM Ellis","year":"2001","unstructured":"Ellis LM  et al. (2001) Overview of angiogenesis: biological implications for antiangiogenic therapy. Semin Oncol 28: 94\u2013104","journal-title":"Semin Oncol"},{"key":"BFncponc0663_CR44","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.ijrobp.2004.08.002","volume":"60","author":"DW Siemann","year":"2004","unstructured":"Siemann DW and Shi W (2004) Efficacy of combined antiangiogenic and vascular disrupting agents in the treatment of solid tumors. Int J Radiat Oncol Biol Phys 60: 1233\u20131240","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BFncponc0663_CR45","first-page":"1153","volume":"35","author":"GJ Russell","year":"1995","unstructured":"Russell GJ  et al. (1995) Inhibition of [3H]mebendazole binding to tubulin by structurally diverse microtubule inhibitors which interact at the colchicine binding site. Biochem Mol Biol Int 35: 1153\u20131159","journal-title":"Biochem Mol Biol Int"},{"key":"BFncponc0663_CR46","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/bjc.1995.138","volume":"71","author":"JA Woods","year":"1995","unstructured":"Woods JA  et al. (1995) The interaction with tubulin of a series of stilbenes based on combretastatin A-04. Br J Cancer 71: 705\u2013711. Comment in: Hemel E  et al. (1983) Interactions of combretastatin, a new plant-derived antimitotic agent, with tubulin. Pharmacology 32: 3863\u20133867","journal-title":"Br J Cancer"},{"key":"BFncponc0663_CR47","first-page":"1829","volume":"57","author":"GG Dark","year":"1997","unstructured":"Dark GG  et al. (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57: 1829\u20131834","journal-title":"Cancer Res"},{"key":"BFncponc0663_CR48","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1172\/JCI24586","volume":"115","author":"L Vincent","year":"2005","unstructured":"Vincent L  et al. (2005) Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest 115: 2992\u20133006","journal-title":"J Clin Invest"},{"key":"BFncponc0663_CR49","first-page":"3408","volume":"62","author":"A Dowlati","year":"2002","unstructured":"Dowlati A  et al. (2002) Phase I pharmacokinetic and translational study of the novel vascular targeting agent Combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62: 3408\u20133416","journal-title":"Cancer Res"},{"key":"BFncponc0663_CR50","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1200\/JCO.2003.05.186","volume":"21","author":"HL Anderson","year":"2003","unstructured":"Anderson HL  et al. (2003) Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A-4 phosphate. J Clin Oncol 21: 2823\u20132830","journal-title":"J Clin Oncol"},{"key":"BFncponc0663_CR51","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1200\/JCO.2003.05.185","volume":"21","author":"GJS Rustin","year":"2003","unstructured":"Rustin GJS  et al. (2003) Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 21: 2815\u20132822","journal-title":"J Clin Oncol"},{"key":"BFncponc0663_CR52","doi-asserted-by":"publisher","first-page":"4428","DOI":"10.1200\/JCO.2003.12.986","volume":"21","author":"JP Stevenson","year":"2003","unstructured":"Stevenson JP  et al. (2003) Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 21: 4428\u20134438","journal-title":"J Clin Oncol"},{"key":"BFncponc0663_CR53","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1158\/1078-0432.CCR-04-1434","volume":"11","author":"JH Bilenker","year":"2005","unstructured":"Bilenker JH  et al. (2005) Phase I trial of combretastatin A-4 phosphate with carboplatin. Clin Cancer Res 11: 1527\u20131533","journal-title":"Clin Cancer Res"},{"issue":"Suppl","key":"BFncponc0663_CR54","first-page":"221S","volume":"23","author":"QS Ng","year":"2005","unstructured":"Ng QS  et al. (2005) Phase Ib trial of combretastatin A4 phosphate in combination with radiotherapy (RT): initial clinical results [abstract # 3117]. Proc Am Soc Clin Oncol 23 (Suppl): 221S","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BFncponc0663_CR55","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1023\/A:1016215015530","volume":"20","author":"S Zhou","year":"2002","unstructured":"Zhou S  et al. (2002) 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy. Invest New Drugs 20: 281\u2013295","journal-title":"Invest New Drugs"},{"issue":"Suppl","key":"BFncponc0663_CR56","first-page":"222S","volume":"23","author":"LR Kelland","year":"2005","unstructured":"Kelland LR  et al. (2005) Plasma levels of 5-hydroxyindole acetic acid (5-HIAA) as a pharmacodynamic marker of blood flow changes induced by the vascular targeting agent (VTA) 5,6-dimethylxanthenone-4-acetic acid, DMXAA [abstract # 3123]. Proc Am Soc Clin Oncol 23 (Suppl): 222S","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BFncponc0663_CR57","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.1200\/JCO.2002.09.144","volume":"20","author":"SM Galbraith","year":"2002","unstructured":"Galbraith SM  et al. (2002) Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 20: 3826\u20133840","journal-title":"J Clin Oncol"},{"key":"BFncponc0663_CR58","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1038\/sj.bjc.6600992","volume":"88","author":"MB Jameson","year":"2003","unstructured":"Jameson MB  et al. (2003) Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 88: 1844\u20131850","journal-title":"Br J Cancer"},{"issue":"Suppl","key":"BFncponc0663_CR59","first-page":"212S","volume":"23","author":"M McKeage","year":"2005","unstructured":"McKeage M  et al. (2005) DART\u2014a phase I safety and dose-finding study of the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in the treatment of refractory tumors [abstract # 3081]. Proc Am Soc Clin Oncol 23 (Suppl): 212S","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BFncponc0663_CR60","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1111\/j.1349-7006.2000.tb01022.x","volume":"91","author":"M Otani","year":"2000","unstructured":"Otani M  et al. (2000) TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death. Jpn J Cancer Res 91: 837\u2013844","journal-title":"Jpn J Cancer Res"},{"key":"BFncponc0663_CR61","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/annonc\/mdh141","volume":"15","author":"P Schoffski","year":"2004","unstructured":"Schoffski P  et al. (2004) Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer. Ann Oncol 15: 671\u2013679","journal-title":"Ann Oncol"},{"key":"BFncponc0663_CR62","doi-asserted-by":"publisher","first-page":"3806","DOI":"10.1158\/1078-0432.CCR-04-1937","volume":"11","author":"MJA de Jonge","year":"2005","unstructured":"de Jonge MJA  et al. (2005) Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors. Clin Cancer Res 11: 3806\u20133813","journal-title":"Clin Cancer Res"},{"issue":"Suppl","key":"BFncponc0663_CR63","first-page":"226S","volume":"23","author":"S Blagen","year":"2005","unstructured":"Blagen S  et al. (2005) Phase I study of intravenous TZT-1027 (T) and carboplatin (C), administered on day 1 (T and C) and day 8 (C) every three weeks in patients (pts) with advanced solid tumors [abstract # 3141]. Proc Am Soc Clin Oncol 23 (Suppl): 226S","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BFncponc0663_CR64","first-page":"1974","volume":"8","author":"DC Blakey","year":"2002","unstructured":"Blakey DC  et al. (2002) Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8: 1974\u20131983","journal-title":"Clin Cancer Res"},{"key":"BFncponc0663_CR65","first-page":"7247","volume":"62","author":"PD Davis","year":"2002","unstructured":"Davis PD  et al. (2002) A novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 62: 7247\u20137253","journal-title":"Cancer Res"},{"issue":"Suppl","key":"BFncponc0663_CR66","first-page":"215S","volume":"22","author":"M Scurr","year":"2004","unstructured":"Scurr M  et al. (2004) Assessment of metabolism, excretion and pharmacokinetics of a single dose of [14C]-ZD6126 in patients with solid malignant tumors [abstract # 3083]. Proc Am Soc Clin Oncol 22 (Suppl): 215S","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl","key":"BFncponc0663_CR67","first-page":"111S","volume":"20","author":"Z DelProposto","year":"2002","unstructured":"DelProposto Z  et al. (2002) MRI evaluation of the effects of the vascular-targeting agent ZD6126 on tumor vasculature [abstract # 440]. Proc Am Soc Clin Oncol 20 (Suppl): 111S","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BFncponc0663_CR68","first-page":"201S","volume":"23","author":"DJ Jonker","year":"2005","unstructured":"Jonker DJ  et al. (2005) A phase I study of the novel molecularly targeted vascular targeting agent, Exherin\u2122 (ADH-1), shows activity in some patients with refractory solid tumors stratified according to N-cadherin expression [abstract # 3038]. Proc Am Soc Clin Oncol 23: 201S","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl","key":"BFncponc0663_CR69","first-page":"156S","volume":"43","author":"P Lejune","year":"2002","unstructured":"Lejune P  et al. (2002) In vivo antitumor activity and tumor necrosis induced by AVE8062, a tumor vasculature targeting agent [abstract #781]. AACR Proceedings 43 (Suppl): 156S","journal-title":"AACR Proceedings"},{"key":"BFncponc0663_CR70","doi-asserted-by":"publisher","first-page":"110S","DOI":"10.1200\/JCO.2002.20.1.110","volume":"20","author":"SM Gadgeel","year":"2002","unstructured":"Gadgeel SM  et al. (2002) A dose-escalation study of the novel vascular-targeting agent, ZD6126, in patients with solid tumors [abstract # 438]. Proc Am Soc Clin Oncol 20: 110S","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BFncponc0663_CR71","doi-asserted-by":"publisher","first-page":"R15","DOI":"10.1172\/JCI8829","volume":"105","author":"G Klement","year":"2000","unstructured":"Klement G  et al. (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105: R15\u2013R24","journal-title":"J Clin Invest"},{"key":"BFncponc0663_CR72","first-page":"1878","volume":"60","author":"T Browder","year":"2000","unstructured":"Browder T  et al. (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60: 1878\u20131886","journal-title":"Cancer Res"}],"container-title":["Nature Clinical Practice Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncponc0663","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc0663.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc0663.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:44:36Z","timestamp":1684442676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncponc0663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":72,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["BFncponc0663"],"URL":"https:\/\/doi.org\/10.1038\/ncponc0663","relation":{},"ISSN":["1743-4254","1743-4262"],"issn-type":[{"value":"1743-4254","type":"print"},{"value":"1743-4262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}